Literature DB >> 29381811

Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B.

Pietro Lampertico1, Thomas Berg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29381811     DOI： 10.1002/hep.29821

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

Review 1.  Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B.

Authors:  Amir M Mohareb; Joseph Larmarange; Arthur Y Kim; Patrick A Coffie; Menan Gérard Kouamé; Anders Boyd; Kenneth A Freedberg; Emily P Hyle
Journal:  Lancet HIV       Date:  2022-07-08       Impact factor: 16.070

2.  Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.

Authors:  Mireia García-López; Sabela Lens; Laura J Pallett; Barbara Testoni; Sergio Rodríguez-Tajes; Zoe Mariño; Concepción Bartres; Ester García-Pras; Thais Leonel; Elena Perpiñán; Juan José Lozano; Francisco Rodríguez-Frías; George Koutsoudakis; Fabien Zoulim; Mala K Maini; Xavier Forns; Sofía Pérez-Del-Pulgar
Journal:  J Hepatol       Date:  2020-12-02       Impact factor: 25.083

Review 3.  Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.

Authors:  Florian van Bömmel; Thomas Berg
Journal:  Hepatol Commun       Date:  2021-06-18

4.  Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA.

Authors:  Marc G Ghany; Anna S Lok
Journal:  J Clin Invest       Date:  2022-09-15       Impact factor: 19.456

Review 5.  Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.

Authors:  Margarita Papatheodoridi; George Papatheodoridis
Journal:  Cells       Date:  2020-02-20       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.